This protocol describes a method to permit the tracking of cells through the cell cycle without requiring the cells to be synchronized. Achieving cell synchronization can be difficult for many cell systems. Standard practice is to block cell cycle progression at a specific stage and then release the accumulated cells producing a wave of cells progressing through the cycle in unison. However, some cell types find this block toxic resulting in abnormal cell cycling, or even mass death. Bromodeoxyuridine (BrdU) uptake can be used to track the cell cycle stage of individual cells. Cells incorporate this synthetic thymidine analog, while synthesizing new DNA during S phase. By providing BrdU for a brief period it is possible to mark a pool of cells that were in S phase while the BrdU was present. These cells can then be tracked through the remainder of the cell cycle and into the next round of replication, permitting the duration of the cell cycle phases to be determined without the need to induce a potentially toxic cell cycle block. It is also possible to determine and correlate the expression of both internal and external proteins during subsequent stages of the cell cycle. These can be used to further refine the assignment of cell cycle stage or assess effects on other cellular functions such as checkpoint activation or cell death.
Introduction
The assessment of cell cycle features and changes that occur in cells during cell cycle progression is fundamental to understanding many aspects of biology, particularly cancer biology. Many agents in development for the treatment of malignancies have profound effects on cell cycle progression or induce cell death via cell cycle dependent-mechanisms. In order to study cell cycle dynamics or cells in a particular phase of the cell cycle, it is usual to synchronize cells. However synchronization methods can have detrimental effects on the cells being studied, potentially confounding the results obtained. 1 Recently the use of fluorescently tagged proteins that are only present at particular phases of the cells cycle have permitted analysis of cell cycle progression in single cells over time 2 , however the cells to be studied need to be genetically manipulated to express these tagged proteins, limiting their use to systems where this can be readily achieved.
The cell cycle consists of two active phases: the synthesis (S) phase, where DNA is replicated and mitosis (M) where cell division takes place. These phases are separated by three gap phases, G 0 , G 1 and G 2 . G 0 or quiescence, is a resting phase where the cell has left the cycle, G 1 is where the cells increase in size prior to DNA replication and G 2 where cell growth continues between completion of DNA replication but before cell division. The progression through the cell cycle is controlled by a number of checkpoints. The G 1 checkpoint is activated when environmental conditions are not supportive of DNA synthesis and prevents entry into S phase. The intra-S phase checkpoint or delay can be triggered by DNA damage that may result in stalled replication forks. During G 2 the fidelity of the replicated DNA is confirmed and if damage is detected then the G 2 checkpoint is activated permitting DNA repair prior to cell division. A final checkpoint during mitosis ensures that chromatids have been correctly aligned at the mitotic plate so that cell division can be successfully completed. 3 Activation of these checkpoints is commonly used to synchronize cell populations. Cell cycle checkpoints can be activated by a number of factors but in cancer biology the most common is detection of DNA damage. The DNA damage response is initiated by the PI3-kinase-like kinases ataxia telangiectasia and Rad3 related (ATR) and ataxia telangiectasia mutated (ATM) that activate the downstream effector kinases Chk1 and Chk2, respectively. 3 A range of events activates Chk1
including stalled replication forks, DNA crosslinks, and ultraviolet radiation damage while Chk2 is primarily activated by double-strand breaks.
Cell Staining
Note: If surface staining of cells is required perform it prior to fixation, ensuring that the cells are kept at 4 °C throughout.
1. Resuspend cells in 100 µl of staining buffer (for optional surface staining, add the recommended volume of antibody to surface antigens and incubate for 30 min at 4 °C). 2. Add 1 ml of staining buffer, centrifuge for 5 min at 150 x g and discard the supernatant.
Note: Specific antibody, concentration, incubation time etc. will vary depending on specific experimental goals. 3. Fixation and Permeabilization 1. Resuspend cells in 100 µl of fixation buffer and incubate for 15 min at room temperature. 2. Add 1 ml of wash buffer, centrifuge for 5 min at 150 x g and discard the supernatant. 3. Resuspend cells in 100 µl of permeabilization buffer and incubate the cells for 10 min on ice. 4. Add 1 ml of wash buffer, centrifuge for 5 min at 150 x g, and discard the supernatant. 5. Resuspend cells in 100 µl of fixation buffer per tube and incubate for 5 min at room temperature. 6. Add 1 ml of wash buffer, centrifuge for 5 min at 150 x g, and discard the supernatant. Note: The protocol can be paused here if required. The fixed cells are stable for several days at 4 °C if resuspended in staining buffer. Remove the staining buffer following centrifugation before proceeding.
4. DNase Treatment 1. Resuspend cells in 100 µl of DNase solution (30 µg of DNase/10 6 cells) and incubate cells for 1 hr at 37 °C.
2. Add 1 ml of wash buffer, centrifuge at 150 x g for 5 min and discard supernatant.
Antibody Staining
Note: Staining for intracellular markers other than BrdU can be performed simultaneously with the BrdU staining. 1. IMPORTANT: Prepare compensation controls consisting of unstained cells and cells labeled with each single fluorochrome. Ideally, use the same antibodies for compensation controls as those used in the experimental tubes. However, if this is not feasible, substitute antibodies to highly expressed antigens conjugated to the same fluorochrome. 2. Resuspend the cells in 50 µl of wash buffer and add 1 µl/10 6 cells of BrdU antibody. Note: Directly conjugated antibodies to other specific intracellular antigens can also be added. NOTE: Antibodies to histone H3 phosphorylated on Ser10 can be used to discriminate between cells in G2 and M, histone H3 is phosphorylated on Ser10 during mitosis. 10 Antibodies to cdc2 phosphorylated on Tyr15 can be used to detect cells that have committed to mitosis. 11 3. Incubate the cells for 20 min at room temperature. 4. Add 1 ml of wash buffer, centrifuge cells at 150 x g for 5 min and discard supernatant. 
Collection of Flow Cytometry Data
Note: The machine required will depend on the number and nature of the fluorochromes used.
Collect the following parameters: FSC-A, SSC-A, FSC-H (FSC-W can be used instead of FSC-H) and 7-AAD fluorescence on a linear scale.
Collect the APC channel on a log scale. Collect any additional channels required for the assessment of surface or internal labels using a log scale. 2. Perform compensation of overlapping signals in emission spectra observed between different fluorochromes before analyzing the samples.
Note: Most flow cytometers will perform this automatically. 3. Collect at least 10,000 events for each sample.
Analysis of Flow Cytometry Data
Note: FlowJo was used in this study for flow cytometry data analysis but other software packages can also be used. The gating strategy is illustrated in Figure 1 .
Representative Results
This methodology can be used to obtain a range of information. A few applications are outlined here.
Assessment of the duration of the cell cycle
To determine the time required for cells to transit through the cell cycle, cells are harvested at various time points following the BrdU pulse. The intervals between assessments can be adapted to the particular cells being analyzed. Hematopoietic cell lines were assessed every hour over a 24 hr period in the absence of any drug treatment to determine the length of cell cycle phases under standard culture conditions. Figure 2 shows a selection of snapshot analysis of NALM6 cells over a 24 hr period. The cells in S phase at the time of the BrdU pulse (i.e. within the BrdU positive gate in Figure 1 ) progressed through G 2 /M, with a peak of cells in that phase of the cell cycle being detected 10 hr after the BrdU pulse. The proportion of BrdU labeled cells in S phase reached its nadir 14 hr after the pulse and almost all cells had returned to G 1 after 17 hr. By 24 hr a proportion of the BrdU labeled cells had reentered S phase as part of their next cell cycle indicating that cells can complete a cell cycle within 24 hr, however most had not yet entered a second round of replication, consistent with the known 36 hr doubling time for these cells.
Cell cycle distribution can be further refined by the inclusion of additional markers. For example, the addition of an antibody to histone H3 phosphorylated on Ser10 (a marker of cells in mitosis) permits the discrimination of cells in mitosis from those in G 2 (left panels of Figure 3 ). Figure 3 ). NALM6 cells had been exposed to 3 nM vincristine for 18 hours after the BrdU pulse. Cells were expected to arrest in mitosis as vincristine targets microtubules. However the cell cycle analysis suggested that the cells had not arrested but transited through to G 0/1 (Figure 3 upper right panel) . The addition of an antibody to histone H3 phosphorylated on Ser10 showed that cells had not exited mitosis (Figure 3 lower right panel) , despite having a reduced DNA content. It is likely that the DNA content was decreased because the cells were undergoing apoptosis and had started to degrade their DNA. Since the cells initiated apoptosis while in mitosis (i.e. with 4N DNA), they appear as S phase or G 0/1 cells instead of the typical apoptotic sub-G 1 peak. In another example, Figure 4 shows how in the presence of a low concentration of RAD001 (an mTOR inhibitor) cells were able to complete the cell cycle but then underwent a delay or arrest in G 0/1 . A higher concentration of RAD001 largely prevented cells from transiting through to G 0/1 . Importantly cells in S phase (i.e. BrdU positive) were shown to preferentially disappear from the culture when RAD001 was added. This suggests that cells passing through G 2 /M were more susceptible to cell death by this agent. 12 It is also possible to examine responses of cells in particular phases of the cell cycle using antibodies to specific antigens. In Figure 5 the activation of the cell cycle checkpoint controlling proteins Chk1 and Chk2 in response to vincristine treatment is shown. Chk1 and Chk2 are activated by phosphorylation on Ser345 and Thr68 respectively. Activation of Chk1 and Chk2 can be seen in cells that appear to have a 2N DNA content but as shown in Figure 5 are likely to be cells in mitosis that have commenced DNA degradation as a result of apoptosis.
It is possible to add drugs at various time points after the BrdU pulse to examine the effect of the agent on cells at various stages of the cell cycle. 
Figure 5: Detection of Changes to Cells in Particular Cell Cycle Phases. The upper panel shows cells gated on the BrdU positive cells as in

Discussion
The ability to analyze the cell cycle is important for the understanding of cancer biology and the mechanism of action of both drugs and genes that influence cell proliferation and growth. While there are a multitude of assays that reportedly measure cell proliferation, the majority only provide a measure that indicates the number cells present. These include assays that measure cell number by direct visualization and counting, metabolic activity or ATP concentration. The main advantage of many of these methods is that they are relatively easy to perform and amenable to microplate formats and automation, making them useful for screening large numbers of conditions or compounds. A shortcoming of many of these methods is that cell loss due to death is not taken into consideration, potentially leading to an underestimate of cell proliferation. Also these methods measure the bulk population and do not permit the study of single cells or the transit of cells through the cell cycle.
Of the commonly used proliferation assays, perhaps the most reliable and accurate are those that measure DNA synthesis. Traditional cell proliferation assays incubate cells for a few hours to overnight with 3 H-thymidine, which is incorporated into newly synthesized DNA. 13 The obvious problem with this method is the use of radioactive materials, but another limitation is that the result measures the average proliferation of a population of cells. BrdU can be similarly used without the radiation issues, although additional steps are required and BrdU is a potential mutagen. However, BrdU has the advantage of being compatible with flow cytometry, permitting the analysis of single cells. 14 Other flow cytometry compatible methods for assessing cell proliferation at the single cell level include a growing number of dyes that label the cell membrane or cellular proteins (e.g. CFSE) that divide between daughter cells, DNA intercalating dyes and cell cycle specific antigen detection by antibodies. The best of cell labeling dyes permit cell division tracking over a number of cell divisions. 15 They provide a direct measure of proliferation, although no information about cell cycle stage or distribution is obtained. The measurement of DNA content using DNA intercalating dyes such as propidium iodide or 7-AAD provide strong cell cycle distribution 16 , but not temporal, data. Even with the assessment of multiple time points it remains impossible to assess the length of the cell cycle or specific cell cycle phases. Cell cycle specific antigens can be used to assess cell cycle phase in an unsynchronized cell population. Commonly used cell cycle specific antigens include Ki-67, 17 which is expressed during the S, G 2 and M phases of the cell cycle but not during G 0/1 , PCNA (proliferating cell nuclear antigen) 18 , and phosphorylation of histone H3. 19 While these provide good data regarding the cell cycle stage, information relating cell cycle dynamics is lacking. 1 The calculation of the duration of the cell cycle and the length of the various cell cycle phases is then possible. Cells can be induced to exit active cell cycling entering G 0 by serum deprivation. Upon the re-addition of serum the cells may then move together into subsequent phases. 20 While this is a reliable method for certain cell types, others, including many transformed cell types, fail to exit the cell cycle and frequently undergo cell death as a result. 21 Indeed our studies found this to be the situation for acute lymphoblastic leukemia cells. Furthermore, cells will often fail to reenter cell cycle in a sufficiently synchronized manner. Chemical methods can be used to induce cell cycle arrest at specific phases of the cell cycle. For example, agents that prevent DNA synthesis (e.g. excess thymidine) or prevent the mitotic spindle formation (e.g. nocodazole) arrest cells in S and M phases respectively, but are toxic and can result in growth disturbances and even death in a significant proportion of the cells. 22 In ALL cells these methods failed to arrest the majority of cells without killing a significant fraction.
Considering that the aim was to assess the effects of a potential anti-leukemic agent on cell cycle parameters, the cell death resulting from synchronization was unacceptable. Despite the description of a large number of methods to synchronize cells, all have shortcomings. The main problems are: an insufficient enrichment for cells in the desired part of the cell cycle, disturbances to the normal physiology of the cell cycle or, as observed, excess toxicity.
The method described here is a simple extension of the long used pulse system, where cells are incubated for a brief period with BrdU to identify cells in S phase. We found a 45 min pulse to be optimal in our system but shorter time periods may be used if sufficient labeling is obtained. By continuing to culture cells after the removal of the BrdU it is possible to track their progression through the remainder of S phase, G 2 , mitosis, G 1 and entry into the next cell cycle. It may be possible to follow the cells further. The advantage of this system is that there is no evidence of toxicity to the cells in the time frame of these experiments and there is minimal disruption to the growth of the cells, as only a couple of media changes are required. The cells are otherwise maintained in continuous culture. The flow cytometry based nature of the method means that it can be combined with the identification of cell subpopulations by additional surface or intracellular staining. We used APC conjugated BrdU antibodies but other conjugates can be substituted to facilitate the development of antibody panels. We used 7-AAD rather than propidium iodide because 7-AAD fluoresces in a single channel maximizing options for multicolor staining. Similarly DAPI or Hoechst can be used as DNA stains but require a UV laser. Tighter CVs for DNA staining can be obtained using ethanol fixation but this frequently compromises antibody staining, limiting the options for additional surface or cytoplasmic stains. The biggest disadvantage is that S phase lasts about 8 hr, so labeled cells may have just entered or about to exit S phase during the pulse period. As a result, the synchronization is not as tight as with some other systems. However, by combining the BrdU labeling with dyes indicating DNA content and antibodies to specific cell cycle dependent proteins, strong data can be obtained.
In order to obtain consistent data it is important to ensure that cells are at the correct concentration and that the cell concentration is consistent across all the conditions being compared. Critically the brightness of the 7-AAD staining is very sensitive to cell concentration. Using an automated cell counting system can help ensure that cell concentrations are consistent in all samples at each step in the process. Another important point is the length of time the cells are exposed to BrdU. Small variations can translate into considerable differences, so it is important that all samples are incubated with BrdU for precisely the same time. Finally, it is important to titrate antibodies to obtain optimal staining and this should be repeated whenever a batch is changed. If all the steps are followed consistently and cell concentrations kept constant then this method will reliably enable the tracking of cells through the cell cycle without the need for synchronization. There is also considerable scope to modify this method to suit particular cell types and address specific questions.
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